Report cover image

Global Angina Pectoris Drugs Market Growth (Status and Outlook) 2025-2031

Publisher LP Information, Inc.
Published Oct 12, 2025
Length 88 Pages
SKU # LPI20468217

Description

According to this study, the global Angina Pectoris Drugs market size will reach US$ 453 million by 2031.

Angina pectoris is a clinical indication characterized by precordial heaviness or discomfort due to transient myocardial ischemia without infarction, elicited by physical exertion or psychological stress. Angina pectoris is categorized as - stable, unstable, microvascular and Prinzmetal / variant. Angina pectoris is an initial presentation of coronary heart disease (CHD) and exerts a major impact on quality of life (QOL), costs to the society and ability to work.

Chronic stable angina pectoris has a prevalence of 2.0 - 4.0% in the seven major markets (U.S., U.K., Germany, France, Italy, Spain, Japan). Heart Disease and Stroke Statistics from American Heart Association estimates indicate that over nine million adults in the U.S. have chronic angina pectoris.

LPI (LP Information)' newest research report, the “Angina Pectoris Drugs Industry Forecast” looks at past sales and reviews total world Angina Pectoris Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Angina Pectoris Drugs sales for 2025 through 2031. With Angina Pectoris Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Angina Pectoris Drugs industry.

This Insight Report provides a comprehensive analysis of the global Angina Pectoris Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Angina Pectoris Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Angina Pectoris Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Angina Pectoris Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Angina Pectoris Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Angina Pectoris Drugs market by product type, application, key players and key regions and countries.

Segmentation by Type:
Beta Blockers
Calcium Antagonists
Anticoagulants
Anti-Platelets
Others

Segmentation by Application:
Hospitals
Clinics
ASCs

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Bayer
AstraZeneca
Gilead
Novartis
GlaxoSmithKline
Merck
Mylan
Teva Pharmaceutical

Please note: The report will take approximately 2 business days to prepare and deliver.

Table of Contents

88 Pages
*This is a tentative TOC and the final deliverable is subject to change.*
1 Scope of the Report
2 Executive Summary
3 Angina Pectoris Drugs Market Size by Player
4 Angina Pectoris Drugs by Region
5 Americas
6 APAC
7 Europe
8 Middle East & Africa
9 Market Drivers, Challenges and Trends
10 Global Angina Pectoris Drugs Market Forecast
11 Key Players Analysis
12 Research Findings and Conclusion

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us